Comparative Pharmacology
Head-to-head clinical analysis: AMPHOTERICIN B versus MONISTAT DERM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMPHOTERICIN B versus MONISTAT DERM.
AMPHOTERICIN B vs MONISTAT-DERM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to ergosterol in fungal cell membranes, forming pores that increase permeability and cause leakage of intracellular contents, leading to cell death.
Miconazole inhibits fungal lanosterol 14α-demethylase, a cytochrome P450 enzyme, thereby blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
0.5-1.5 mg/kg/day IV over 2-6 hours; for invasive aspergillosis, 1 mg/kg/day; for cryptococcal meningitis, 0.7 mg/kg/day IV in combination with flucytosine; liposomal formulation: 3-5 mg/kg/day IV. Maximum dose: 1.5 mg/kg/day for conventional amphotericin B deoxycholate.
Topical: Apply once daily to affected areas for 2-4 weeks. Vaginal: One 200 mg suppository at bedtime for 3 days, or one 100 mg suppository at bedtime for 7 days, or one 1200 mg suppository as a single dose.
None Documented
None Documented
Clinical Note
moderateAmphotericin B + Digoxin
"The risk or severity of adverse effects can be increased when Amphotericin B is combined with Digoxin."
Clinical Note
moderateAmphotericin B + Digitoxin
"The risk or severity of adverse effects can be increased when Amphotericin B is combined with Digitoxin."
Clinical Note
moderateAmphotericin B + Deslanoside
"The risk or severity of adverse effects can be increased when Amphotericin B is combined with Deslanoside."
Clinical Note
moderateTerminal half-life: 24–48 hours initially, prolonged to 15 days with repeated dosing due to tissue redistribution.
Terminal elimination half-life is approximately 24–30 hours, supporting twice-daily or once-daily dosing for dermatologic infections.
Renal: ~2-5% unchanged; biliary/fecal: ~40% as metabolites; extensive tissue binding delays excretion.
Primarily fecal (biliary) elimination as unchanged drug and metabolites; <1% renal excretion of unchanged drug.
Category C
Category C
Antifungal
Antifungal
Amphotericin B + Acetyldigitoxin
"The risk or severity of adverse effects can be increased when Amphotericin B is combined with Acetyldigitoxin."